India, Aug. 13 -- MapLight Therapeutics, Inc. (MPLT) announced it has priced a $150 million private placement financing with institutional and accredited investors.
The deal includes 9.2 million shares of common stock at $11.38 per share and 4.0 million pre-funded warrants at $11.3799 each, exercisable at $0.0001 per share with no expiration.
The financing is expected to close on August 14, 2026, subject to customary conditions.
Use of Proceeds
Maplight intends to use the funds to support ML-007C-MA, its lead candidate for central nervous system disorders. Proceeds will advance the ongoing VISTA Phase 2 study in Alzheimer's disease psychosis and the ZEPHYR-2 registrational Phase 3 study in schizophrenia, alongside an open-label safety s...